On June 8, Insilico Medicine fell 5.69% in regular trading, trading at 35.68 HKD/share, with trading volume of approximately 54.76 million HKD.

On the news front, the company's cornerstone investors and employee restricted shares lock-up period is set to expire on June 29, with approximately 453 million shares (representing 81.25% of total share capital) facing potential unlocking. Market concerns over imminent selling pressure have intensified offloading behavior. Additionally, the company previously clarified it has no definite plans for a secondary listing in Abu Dhabi, dashing market expectations for expanded international financing channels.

Within the Life Sciences Tools & Services sector, broad weakness further amplified the decline. WuXi Biologics fell 5.38%, WuXi XDC dropped 4.61%, GenScript Biotech declined 4.26%, XtalPi lost 3.2%, and WuXi AppTec fell 2.89%. The stock has now accumulated a decline of nearly 40% over the past month, with sustained downward momentum.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)